Počet záznamov: 1
Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE"
- Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE" / Sufliarsky J.. Onkológia Roč. 12, č. 5 (2017), s. 379
článok
Počet záznamov: 1